{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:00:57Z","timestamp":1784707257902,"version":"3.55.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"1184","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Localized treatment of oligometastatic liver disease can improve both local control and survival. The liver is a frequent site of metastases from colorectal, breast, and lung cancers, but most patients are not eligible for surgical resection due to lesion number, location, or comorbidities. For these patients, non-surgical ablative methods such as radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) are widely used. While RFA has been the traditional approach, SBRT is emerging as a promising alternative, offering precise, non-invasive treatment. SBRT may be especially useful for larger lesions or tumors in locations where RFA is difficult to perform. However, high-quality evidence and large-scale trials are still needed to confirm its efficacy and define its role. This review compares the strengths and limitations of both methods and provides practical guidance for clinical decision-making in the treatment of patients with inoperable liver metastases.<\/jats:p>","DOI":"10.1093\/bjr\/tqag147","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:31:09Z","timestamp":1781152269000},"page":"1529-1537","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of stereotactic body radiotherapy and percutaneous radiofrequency ablation for oligometastatic liver disease\u2014radiation oncologists\u2019 perspective and practice guideline"],"prefix":"10.1093","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8435-8074","authenticated-orcid":false,"given":"Banu","family":"Atalar","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Acibadem MAA University School of Medicine , Istanbul, 34457, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceren","family":"Atahan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Acibadem MAA University School of Medicine , Istanbul, 34457, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[{"name":"University of Western Ontario, London Regional Cancer Program, London, ON Department of Radiation Oncology, N6A 3K7,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Cardarelli Leite","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre, Schulich School of Medicine and Dentistry, University of Western Ontario , London, ON, N6A 3K7,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Mahadevan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, NYU Langone Health , New York City, NY, 10016,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Ugurluer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Acibadem MAA University School of Medicine , Istanbul, 34457, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enis","family":"Ozyar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Acibadem MAA University School of Medicine , Istanbul, 34457, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026072203070969200_tqag147-B1","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026072203070969200_tqag147-B2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/S13014-018-1185-9","article-title":"Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up","volume":"13","author":"Scorsetti","year":"2018","journal-title":"Radiat Oncol"},{"key":"2026072203070969200_tqag147-B3","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3390\/DIAGNOSTICS12061300","article-title":"Image-guided percutaneous ablation for primary and metastatic tumors","volume":"12","author":"Mansur","year":"2022","journal-title":"Diagnostics"},{"key":"2026072203070969200_tqag147-B4","doi-asserted-by":"publisher","first-page":"e990","DOI":"10.1634\/theoncologist.2018-0337","article-title":"Radiofrequency ablation and microwave ablation in liver tumors: an update","volume":"24","author":"Izzo","year":"2019","journal-title":"Oncologist"},{"key":"2026072203070969200_tqag147-B5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S1091-255X(01)80085-8","article-title":"Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches","volume":"5","author":"Machi","year":"2001","journal-title":"J Gastrointestinal Surg"},{"key":"2026072203070969200_tqag147-B6","doi-asserted-by":"publisher","first-page":"100594","DOI":"10.1016\/J.JHEPR.2022.100594\/ATTACHMENT\/B7CE0BE7-DEBB-433C-BB82-A341F72D7D7D\/MMC3.PDF","article-title":"Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: a hybrid meta-analysis","volume":"5","author":"Rim","year":"2023","journal-title":"JHEP Rep"},{"key":"2026072203070969200_tqag147-B7","author":"Study Details. Collision XL: Unresectable Colorectal Liver Metastases (3-5 cm):","year":"2024"},{"key":"2026072203070969200_tqag147-B8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1080\/0284186X.2021.2009563","article-title":"Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer-a systematic review and network meta-analysis of survival data","volume":"61","author":"Chow","year":"2022","journal-title":"Acta Oncol"},{"key":"2026072203070969200_tqag147-B9","author":"Study Details. Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease","year":"2024"},{"key":"2026072203070969200_tqag147-B10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(24)00660-0","article-title":"Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial","volume":"26","author":"van der Lei","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026072203070969200_tqag147-B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000510909","article-title":"Laparoscopic liver resection versus percutaneous radiofrequency ablation for small single nodular hepatocellular carcinoma: comparison of treatment outcomes","volume":"10","author":"Lee","year":"2021","journal-title":"Liver Cancer"},{"key":"2026072203070969200_tqag147-B12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Schefter","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026072203070969200_tqag147-B13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690\/ASSET\/B9EDBA10-3DE7-4BB9-B109-3A1D6732259B\/ASSETS\/IMAGES\/LARGE\/JCO.22.01690TA2.JPG","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026072203070969200_tqag147-B14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/J.ANNONC.2022.10.003\/ASSET\/73A9D40C-D7A8-4E23-9CE1-42D269E4BD97\/MAIN.ASSETS\/GR5.JPG","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"2026072203070969200_tqag147-B15","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1200\/JCO.2013.49.9202","article-title":"Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases","volume":"31","author":"Soliman","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026072203070969200_tqag147-B16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3857\/ROJ.2020.00976","article-title":"Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial clinical experience","volume":"39","author":"Ugurluer","year":"2021","journal-title":"Radiat Oncol J"},{"key":"2026072203070969200_tqag147-B17","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1016\/J.PRRO.2024.09.011","article-title":"Stereotactic body radiotherapy for liver metastases: systematic review and meta-analysis with international stereotactic radiosurgery society (ISRS) practice guidelines","volume":"15","author":"Franzese","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"2026072203070969200_tqag147-B18","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.3390\/CANCERS13174303","article-title":"Thermal ablation versus stereotactic ablative body radiotherapy to treat unresectable colorectal liver metastases: a comparative analysis from the prospective Amsterdam CORE registry","volume":"13","author":"Nieuwenhuizen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026072203070969200_tqag147-B19","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/J.IJROBP.2017.07.030","article-title":"Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer","volume":"99","author":"Joo","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026072203070969200_tqag147-B20","doi-asserted-by":"publisher","first-page":"djx015","DOI":"10.1093\/JNCI\/DJX015","article-title":"Local treatment of unresectable colorectal liver metastases: Results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"JNCI"},{"key":"2026072203070969200_tqag147-B21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.4143\/CRT.2021.674","article-title":"Radiofrequency ablation versus stereotactic body radiation therapy in the treatment of colorectal cancer liver metastases","volume":"54","author":"Yu","year":"2022","journal-title":"Cancer Res Treat"},{"key":"2026072203070969200_tqag147-B22","doi-asserted-by":"publisher","first-page":"100594","DOI":"10.1016\/j.jhepr.2022.100594","article-title":"Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: a hybrid meta-analysis","volume":"5","author":"Chai Hong Rim","year":"2023","journal-title":"J Hepatol"},{"key":"2026072203070969200_tqag147-B23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/J.SEMRADONC.2022.11.008","article-title":"The role of stereotactic body radiation therapy in the management of liver metastases","volume":"33","author":"Lee","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"2026072203070969200_tqag147-B24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1245\/S10434-010-1405-5","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases","volume":"18","author":"Rule","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2026072203070969200_tqag147-B25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.CANRAD.2023.04.008","article-title":"Stereotactic body radiation therapy for liver metastases in oligometastatic disease","volume":"28","author":"Jaksic","year":"2024","journal-title":"Cancer Radiother"},{"key":"2026072203070969200_tqag147-B26","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1007\/S12094-024-03403-W\/TABLES\/3","article-title":"SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases","volume":"26","author":"Rodr\u00edguez","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"2026072203070969200_tqag147-B27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1748-717X-9-112","article-title":"Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients","volume":"9","author":"Yamashita","year":"2014","journal-title":"Radiat Oncol"},{"key":"2026072203070969200_tqag147-B28","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600\/ASSET\/IMAGES\/ZLJ9990984950004.JPEG","article-title":"Phase I study of individualized stereotactic body radiotherapy of liver metastases","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026072203070969200_tqag147-B29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/S11912-022-01248-6","article-title":"Microwave ablation, radiofrequency ablation, irreversible electroporation, and stereotactic ablative body radiotherapy for intermediate size (3-5 cm) unresectable colorectal liver metastases: a systematic review and meta-analysis","volume":"24","author":"Nieuwenhuizen","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2026072203070969200_tqag147-B30","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/J.IJROBP.2017.12.014","article-title":"Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases","volume":"100","author":"Jackson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026072203070969200_tqag147-B31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/S12885-018-4191-2","article-title":"The SBRT database initiative of the German society for radiation oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","author":"Andratschke","year":"2018","journal-title":"BMC Cancer"},{"key":"2026072203070969200_tqag147-B32","doi-asserted-by":"publisher","first-page":"9230","DOI":"10.3390\/curroncol30100667","article-title":"Local control following stereotactic body radiation therapy for liver oligometastases: lessons from a quarter century","volume":"30","author":"Mheid","year":"2023","journal-title":"Curr Oncol"},{"key":"2026072203070969200_tqag147-B33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/JCM12031183","article-title":"Stereotactic MR-guided radiotherapy for liver metastases: first results of the Montpellier prospective registry study","volume":"12","author":"Bordeau","year":"2023","journal-title":"J Clin Med"},{"key":"2026072203070969200_tqag147-B34","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/J.IJROBP.2020.11.045","article-title":"The Dutch-Belgian registry of stereotactic body radiation therapy for liver metastases: clinical outcomes of 515 patients and 668 metastases","volume":"109","author":"M\u00e9ndez Romero","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026072203070969200_tqag147-B35","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1002\/CNCR.25997","article-title":"Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis","volume":"117","author":"Chang","year":"2011","journal-title":"Cancer"},{"key":"2026072203070969200_tqag147-B36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/J.RADONC.2014.12.003","article-title":"Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases","volume":"114","author":"Fode","year":"2015","journal-title":"Radiother Oncol"},{"key":"2026072203070969200_tqag147-B37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/S13014-018-0969-2","article-title":"Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch\u00ae patient registry","volume":"13","author":"Mahadevan","year":"2018","journal-title":"Radiat Oncol"},{"key":"2026072203070969200_tqag147-B38","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/J.IJROBP.2016.03.050","article-title":"Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy","volume":"95","author":"Ahmed","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026072203070969200_tqag147-B39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","article-title":"Stereotactic body radiotherapy for oligo-metastatic liver disease - influence of pre-treatment chemotherapy and histology on local tumor control","volume":"123","author":"Klement","year":"2017","journal-title":"Radiother Oncol"},{"key":"2026072203070969200_tqag147-B40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1748-717X-6-34\/FIGURES\/4","article-title":"Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control","volume":"6","author":"Stinauer","year":"2011","journal-title":"Radiat Oncol"},{"key":"2026072203070969200_tqag147-B41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/S10585-024-10301-6","article-title":"Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro\/eortc consensus recommendations","volume":"41","author":"Pezzulla","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"2026072203070969200_tqag147-B42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/J.IJROBP.2017.12.288","article-title":"Local control after stereotactic body radiation therapy for liver tumors","volume":"110","author":"Ohri","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026072203070969200_tqag147-B43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1148\/RADIOL.2015142489","article-title":"Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes\u2014a 10-year experience at a single center","volume":"278","author":"Shady","year":"2016","journal-title":"Radiology"},{"key":"2026072203070969200_tqag147-B44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/J.RADONC.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review","volume":"145","author":"Lee","year":"2020","journal-title":"Radiother Oncol"},{"key":"2026072203070969200_tqag147-B45","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/j.prro.2019.02.013","article-title":"NRG oncology\/RTOG 0438: a phase 1 trial of highly conformal radiation therapy for liver metastases","volume":"9","author":"Dawson","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"2026072203070969200_tqag147-B46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/S00270-009-9736-Y","article-title":"Quality improvement guidelines for radiofrequency ablation of liver tumours","volume":"33","author":"Crocetti","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026072203070969200_tqag147-B47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jhep.2020.03.005","article-title":"Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma","volume":"73","author":"Kim","year":"2020","journal-title":"J Hepatol"},{"key":"2026072203070969200_tqag147-B48","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1186\/S12885-021-08488-Y\/TABLES\/5","article-title":"Analysis of using high-precision radiotherapy in the treatment of liver metastases regarding toxicity and survival","volume":"21","author":"Voglhuber","year":"2021","journal-title":"BMC Cancer"},{"key":"2026072203070969200_tqag147-B49","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3857\/ROJ.2017.00024","article-title":"Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors","volume":"35","author":"Cha","year":"2017","journal-title":"Radiat Oncol J"},{"key":"2026072203070969200_tqag147-B50","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.rpor.2016.10.003","article-title":"Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy","volume":"22","author":"M\u00e9ndez Romero","year":"2017","journal-title":"Rep Pract Oncol Radiother"},{"key":"2026072203070969200_tqag147-B51","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/J.BREAST.2018.09.006\/ASSET\/31687FCF-CEBD-4AA9-86A3-51FDF4B1F5E9\/MAIN.ASSETS\/EGI10SRL008QD6.JPG","article-title":"Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy","volume":"42","author":"Onal","year":"2018","journal-title":"Breast"},{"key":"2026072203070969200_tqag147-B52","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/S00432-014-1833-X","article-title":"Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026072203070969200_tqag147-B53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000514914","article-title":"Stereotactic ablative radiotherapy for the management of liver metastases from neuroendocrine neoplasms: a preliminary study","volume":"112","author":"Hudson","year":"2022","journal-title":"Neuroendocrinology"},{"key":"2026072203070969200_tqag147-B54","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026072203070969200_tqag147-B55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/J.RADONC.2018.12.013","article-title":"Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma","volume":"131","author":"Kim","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026072203070969200_tqag147-B56","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/J.RPOR.2016.07.006","article-title":"Image guided SBRT for multiple liver metastases with ExacTrac\u00ae adaptive gating","volume":"22","author":"Rubio","year":"2017","journal-title":"Rep Pract Oncol Radiother"},{"key":"2026072203070969200_tqag147-B57","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC intergroup phase II study (EORTC 40004)","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"2026072203070969200_tqag147-B58","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1097\/MS9.0000000000000954","article-title":"Systemic chemotherapy combined with radiofrequency ablation for colorectal cancer with liver metastasis: a retrospective cohort study","volume":"85","author":"Tran","year":"2023","journal-title":"Ann Med Surg"},{"key":"2026072203070969200_tqag147-B59","doi-asserted-by":"publisher","first-page":"114264","DOI":"10.1016\/J.EJCA.2024.114264","article-title":"Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials","volume":"209","author":"Lynch","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026072203070969200_tqag147-B60","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026072203070969200_tqag147-B61","author":"4026-Hepatic Metastases Stereotactic EBRT. Eviq. Accessed October 16","year":"2024"},{"key":"2026072203070969200_tqag147-B62","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/J.IJROBP.2016.02.045","article-title":"Cost-effectiveness analysis of stereotactic body radiation therapy compared with radiofrequency ablation for inoperable colorectal liver metastases","volume":"95","author":"Kim","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqag147\/68508266\/tqag147.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1184\/1529\/68508266\/tqag147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1184\/1529\/68508266\/tqag147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:07:14Z","timestamp":1784704034000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/99\/1184\/1529\/8705527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":62,"journal-issue":{"issue":"1184","published-online":{"date-parts":[[2026,6,10]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqag147","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,10]]}}}